HomeCompareLBTSF vs EQR

LBTSF vs EQR: Dividend Comparison 2026

LBTSF yields 1.34% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LBTSF wins by $12.85M in total portfolio value· pulled ahead in Year 4
10 years
LBTSF
LBTSF
● Live price
1.34%
Share price
$15.35
Annual div
$0.21
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$12.89M
Annual income
$11,275,798.89
Full LBTSF calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — LBTSF vs EQR

📍 LBTSF pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLBTSFEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LBTSF + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LBTSF pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LBTSF
Annual income on $10K today (after 15% tax)
$114.07/yr
After 10yr DRIP, annual income (after tax)
$9,584,429.06/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, LBTSF beats the other by $9,581,182.39/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LBTSF + EQR for your $10,000?

LBTSF: 50%EQR: 50%
100% EQR50/50100% LBTSF
Portfolio after 10yr
$6.47M
Annual income
$5,639,809.24/yr
Blended yield
87.23%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

LBTSF
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
3.0
Piotroski
7/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LBTSF buys
0
EQR buys
0
No recent congressional trades found for LBTSF or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLBTSFEQR
Forward yield1.34%4.73%
Annual dividend / share$0.21$2.77
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%15.8%
Portfolio after 10y$12.89M$40.5K
Annual income after 10y$11,275,798.89$3,819.61
Total dividends collected$12.74M$16.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold

Year-by-year: LBTSF vs EQR ($10,000, DRIP)

YearLBTSF PortfolioLBTSF Income/yrEQR PortfolioEQR Income/yrGap
1$10,968$268.40$11,248$547.57$280.00EQR
2$12,286$550.27$12,701$666.53$415.00EQR
3$14,299$1,152.15$14,405$814.59$106.00EQR
4← crossover$17,806$2,506.24$16,413$999.84+$1.4KLBTSF
5$24,886$5,833.59$18,795$1,232.92+$6.1KLBTSF
6$41,867$15,239.53$21,639$1,527.95+$20.2KLBTSF
7$92,721$47,922.73$25,057$1,903.80+$67.7KLBTSF
8$297,587$198,376.17$29,197$2,385.87+$268.4KLBTSF
9$1,508,490$1,190,071.76$34,250$3,008.70+$1.47MLBTSF
10$12,889,884$11,275,798.89$40,467$3,819.61+$12.85MLBTSF

LBTSF vs EQR: Complete Analysis 2026

LBTSFStock

Almirall, S.A., a biopharmaceutical company, engages in the research, development, manufacture, and sale of skin-health related medicines in Europe, the United States, and internationally. The company offers its products for dermatological diseases comprising actinic keratosis, atopic dermatitis, androgenic alopecia, psoriasis, onychomycosis, oncodermatology, acne, and orphan indications, as well as for cardiovascular, musculo-skeletal, respiratory, and nervous system; alimentary tract and metabolism; antiinfectives for systemic use; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. Its products include Ilumetri, Solaraze, Actikerall, Ciclopoli, Skilarence, Aczone, Decoderm, Cordran Tape, Azelex, Klisyri, Tazorac, Seysara, Veltin, Almax, Ebastel, Sativex, Crestor, and Efficib/Tesavel. Almirall, S.A. has collaboration and partnership agreements with Tyris Therapeutics, BIOMAP, the University of Dundee, Kaken Pharmaceutical Co Ltd., Ichnos Sciences Inc., the University Carlos III Madrid and MEDINA Foundation, 23andMe, Inc., HitGen Ltd., WuXi Biologics, Eli Lilly and Company, and Athenex, Inc. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.

Full LBTSF Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this LBTSF vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LBTSF vs SCHDLBTSF vs JEPILBTSF vs OLBTSF vs KOLBTSF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.